Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP

Pregno, Patrizia; Chiappella, Annalisa; Bellò, Marilena; Botto, Barbara; Ferrero, Simone; Franceschetti, Silvia; Giunta, Francesca; Ladetto, Marco; Limerutti, Giorgio; Menga, Massimo; Nicolosi, Maura; Priolo, G; Puccini, Benedetta; Rigacci, Luigi; Salvi, Flavia; Vaggelli, Luca; Passera, Roberto; Bisi, G; Vitolo, Umberto

doi:10.1182/blood-2011-06-359943

Cited by 211 publications

(166 citation statements)

References 32 publications

Supporting

Mentioning

148

Contrasting

Unclassified

Order By: Relevance

“…A series of 37 patients with PMBCL, all evaluated with 18 FDG-PET at staging and restaging before RT and treated with R-CT followed by mediastinal RT, were included in the study.…”

Section: Methodsmentioning

confidence: 99%

“…The median interval between the end of R-CT and the start of mediastinal RT was 53 days (range, 20-86 days). 18 FDG-PET scans were acquired from the orbits to the proximal third of the thighs. Scans were acquired on a Philips Gemini Tomograph or a General Electric Discovery ST scanner.…”

Section: Methodsmentioning

confidence: 99%

“…In the past years, computed tomography (CT) or a combination of CT and 67 Gallium scans have been considered the gold standard. 18 Fluorodeoxyglucose positron emission tomography ( 18 FDG-PET) recently emerged as an important tool for chemosensitivity evaluation and response assessment in aggressive 18 FDG-avid lymphomas; its contribution in PMBCL management is therefore increasing, based on conventional response evaluation criteria defined for aggressive lymphomas and considering several limitations of morphologic radiologic findings in evaluating residual mediastinal tissue (12). A prospective international clinical trial lead by the collaborative International Extranodal Lymphoma Study Group, the IELSG 37 study (recently opened to accrual of patients) was designed with the aim of investigating the role of consolidation RT in 18 FDG-PET-negative patients.…”

Section: Introductionmentioning

confidence: 99%

“…18 Fluorodeoxyglucose positron emission tomography ( 18 FDG-PET) recently emerged as an important tool for chemosensitivity evaluation and response assessment in aggressive 18 FDG-avid lymphomas; its contribution in PMBCL management is therefore increasing, based on conventional response evaluation criteria defined for aggressive lymphomas and considering several limitations of morphologic radiologic findings in evaluating residual mediastinal tissue (12). A prospective international clinical trial lead by the collaborative International Extranodal Lymphoma Study Group, the IELSG 37 study (recently opened to accrual of patients) was designed with the aim of investigating the role of consolidation RT in 18 FDG-PET-negative patients. In this study, for 18 FDG-PET-positive patients (expected to be approximately 50%), the decision about further treatment is left to the treating physicians, underlining the uncertainty in the optimal management of patients with residual disease at functional imaging after R-CT.…”

Section: Introductionmentioning

confidence: 99%

“…A prospective international clinical trial lead by the collaborative International Extranodal Lymphoma Study Group, the IELSG 37 study (recently opened to accrual of patients) was designed with the aim of investigating the role of consolidation RT in 18 FDG-PET-negative patients. In this study, for 18 FDG-PET-positive patients (expected to be approximately 50%), the decision about further treatment is left to the treating physicians, underlining the uncertainty in the optimal management of patients with residual disease at functional imaging after R-CT. The introduction of an international validated scoring system for functional imaging interpretation, the Deauville 5-point system 13 and 14, might make it possible to better stratify patients on the basis of metabolic response, adapting the treatment strategy.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Radiation Therapy in Primary Mediastinal B-Cell Lymphoma With Positron Emission Tomography Positivity After Rituximab Chemotherapy

Filippi¹,

Piva²,

Giunta³

et al. 2013

International Journal of Radiation Oncology*Biology*Physics

Self Cite

View full text Add to dashboard Cite

“…A series of 37 patients with PMBCL, all evaluated with 18 FDG-PET at staging and restaging before RT and treated with R-CT followed by mediastinal RT, were included in the study.…”

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Radiation Therapy in Primary Mediastinal B-Cell Lymphoma With Positron Emission Tomography Positivity After Rituximab Chemotherapy

Filippi¹,

Piva²,

Giunta³

et al. 2013

International Journal of Radiation Oncology*Biology*Physics

Self Cite

View full text Add to dashboard Cite

Utility of interim and end‐of‐treatment PET/CT in peripheral T‐cell lymphomas: A review of 124 patients

et al. 2015

View full text Add to dashboard Cite

According to the updated guidelines for imaging in lymphoma, 18F-FDG positron emission tomography/ computed tomography (PET/CT) is recommended for staging and evaluation of treatment response in FDGavid lymphomas. The purpose of the study was to evaluate the utility of PET/CT in nodal peripheral T-cell lymphomas (PTCL). Patients with newly diagnosed nodal PTCL (peripheral T-cell lymphoma NOS, anaplastic large-cell lymphoma, or angioimmunoblastic T-cell lymphoma) seen at five Danish hematology centers during the period 2006 to 2012 were included, if they had been pretherapeutically staged with PET/CT. Medical records were reviewed for baseline clinical and follow-up information. Staging, interim (I-PET), and end-of-treatment PET/CT (E-PET) studies were centrally reviewed, and reported using the Deauville 5-point score (DS). A total of 124 patients fulfilled the inclusion criteria. The median age was 58 years, and 88% received CHOP/CHOP-like therapy. Five years PFS and OS of the study population was 36.8% (95% CI 27.3-46.4) and 49.7% (95% CI 38.9-59.6), respectively. The presence of PET/CT-ascertained lung and/or liver involvement was associated with a worse outcome. The sensitivity of PET/CT for detecting biopsy-defined bone marrow involvement was only 18% (95% CI 4-43). An interim DS >3 was not prognostic for worse OS and PFS among CHOP/CHOP-like treated patients in uni-or multivariate analyses. A DS >3 after treatment predicted a worse prognosis. In conclusion, I-PET was not predictive of outcome in CHOP/CHOP-like treated PTCL patients when using the DS. Prospective studies are needed to determine the optimal use of PET/CT in PTCL including the role of quantitative PET/CT analysis.

show abstract

Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B‐cell lymphoma

Sun

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

Purpose The role of interim 18 F‐FDG PET/CT (iPET/CT) in diffuse large B‐cell lymphoma (DLBCL) remains controversial. The purpose of this study was to assess the prognostic value of iPET/CT in patients with newly diagnosed DLBCL according to visual and semiquantitative interpretation methods. Methods A total of 129 newly diagnosed DLBCL patients with baseline PET/CT data were retrospectively screened. The iPET/CT findings were evaluated by the Deauville 5‐point scale (DS) and ΔSUVmax. Furthermore, the reduction in SUVmax incorporated with tumor size (ΔSUVmax*ΔSLD) was calculated. The optimal cutoff values of ΔSUVmax and ΔSUVmax*ΔSLD were determined by receiver operating characteristic (ROC) analysis. Kaplan‐Meier analysis was applied to test for the influence of prognostic values. Univariate and multivariate analyses were conducted to examine the potential independent impacts of iPET/CT. Results Seventy‐seven patients with PET/CT images acquired both at baseline and after four cycles of chemotherapy were finally enrolled. The optimal cutoff values for ΔSUVmax and ΔSUVmax*ΔSLD were 74% and 30%, respectively. After a median follow‐up of 23 months, iPET/CT findings were significant predictors of PFS and OS whenever iPET/CT was interpreted by DS, ΔSUVmax, or ΔSUVmax*ΔSLD methods. ΔSUVmax‐based methods were more accurate than those based on DS. The IPI, DS, ΔSUVmax, and ΔSUVmax*ΔSLD were predictive in univariate analyses. However, in the multivariate analysis, only IPI and ΔSUVmax remained independent predictors of PFS and OS. Conclusions Interim PET/CT may help to identify DLBCL patients with different prognoses. ΔSUVmax analysis shows the best accuracy and the strongest predictive value among these three methods. ΔSUVmax*ΔSLD may be a promising parameter to interpret iPET/CT images, reflecting both the changes in tumor size and metabolic activity.

show abstract

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP

Abstract: Role of interim-PET (I-PET) in diffuse large

Cited by 211 publications

References 32 publications

Radiation Therapy in Primary Mediastinal B-Cell Lymphoma With Positron Emission Tomography Positivity After Rituximab Chemotherapy

Radiation Therapy in Primary Mediastinal B-Cell Lymphoma With Positron Emission Tomography Positivity After Rituximab Chemotherapy

Utility of interim and end‐of‐treatment PET/CT in peripheral T‐cell lymphomas: A review of 124 patients

Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B‐cell lymphoma

Contact Info

Product

Resources

About